GSK 2890457

Drug Profile

GSK 2890457

Alternative Names: GSK-2890457

Latest Information Update: 20 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 30 Sep 2013 GlaxoSmithKline completes a phase II trial in Obesity in the USA (NCT01725126)
  • 28 Feb 2013 GlaxoSmithKline initiates enrolment in a phase II trial for Obesity in the USA (NCT01725126)
  • 08 Nov 2012 Planned phase-II clinical trials in Obesity in USA (PO, powder capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top